Monte Rosa Therapeutics, Inc. (GLUE)
GLUE Stock Price Chart
Explore Monte Rosa Therapeutics, Inc. interactive price chart. Choose custom timeframes to analyze GLUE price movements and trends.
GLUE Company Profile
Discover essential business fundamentals and corporate details for Monte Rosa Therapeutics, Inc. (GLUE) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
24 Jun 2021
Employees
142.00
Website
https://www.monterosatx.comCEO
Markus Warmuth
Description
Monte Rosa Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel small molecule precision medicines that employ the body's natural mechanisms to selectively degrade therapeutically relevant proteins. It develops an oral molecular glue degrader for GSPT1, a translational termination factor and degron-containing protein for the treatment of Myc-driven cancers. The company also develops CDK2 to treat ovarian, uterine, and breast cancers; NEK7 for the treatment of inflammatory diseases, such as Crohn's disease, neurodegenerative disease, diabetes, and liver disease; VAV1, a target protein for autoimmune diseases; and BCL11A, a therapeutically-relevant protein in hemoglobinopathies. Monte Rosa Therapeutics, Inc. was incorporated in 2019 and is headquartered in Boston, Massachusetts.
GLUE Financial Timeline
Browse a chronological timeline of Monte Rosa Therapeutics, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 6 May 2026
Upcoming earnings on 6 Nov 2025
EPS estimate is -$0.28.
Earnings released on 7 Aug 2025
EPS came in at -$0.15 surpassing the estimated -$0.31 by +51.61%, while revenue for the quarter reached $23.19M , beating expectations by +140.57%.
Earnings released on 8 May 2025
EPS came in at $0.57 surpassing the estimated -$0.24 by +337.50%, while revenue for the quarter reached $84.93M , beating expectations by +526.01%.
Earnings released on 20 Mar 2025
EPS came in at $0.23 surpassing the estimated -$0.37 by +162.16%, while revenue for the quarter reached $60.65M , beating expectations by +29.95%.
Earnings released on 7 Nov 2024
EPS came in at -$0.29 surpassing the estimated -$0.45 by +35.56%, while revenue for the quarter reached $9.22M , beating expectations by +249.34%.
Earnings released on 8 Aug 2024
EPS came in at -$0.43 surpassing the estimated -$0.50 by +14.00%, while revenue for the quarter reached $4.70M , beating expectations by +248.07%.
Earnings released on 9 May 2024
EPS came in at -$0.53 surpassing the estimated -$0.56 by +5.36%, while revenue for the quarter reached $1.06M , missing expectations by -24.00%.
Earnings released on 14 Mar 2024
EPS came in at -$0.58 falling short of the estimated -$0.57 by -1.75%, while revenue for the quarter reached $8.75M , beating expectations by +148.08%.
Earnings released on 9 Nov 2023
EPS came in at -$0.70 surpassing the estimated -$0.75 by +6.67%.
Earnings released on 10 Aug 2023
EPS came in at -$0.71 surpassing the estimated -$0.72 by +1.39%.
Earnings released on 11 May 2023
EPS came in at -$0.65 surpassing the estimated -$0.70 by +7.14%.
Earnings released on 16 Mar 2023
EPS came in at -$0.63 surpassing the estimated -$0.64 by +1.56%.
Earnings released on 10 Nov 2022
EPS came in at -$0.58 surpassing the estimated -$0.61 by +4.92%.
Earnings released on 11 Aug 2022
EPS came in at -$0.57 falling short of the estimated -$0.54 by -5.56%.
Earnings released on 11 May 2022
EPS came in at -$0.51 surpassing the estimated -$0.53 by +3.77%.
Earnings released on 29 Mar 2022
EPS came in at -$0.93 falling short of the estimated -$0.50 by -86.00%.
Earnings released on 10 Nov 2021
EPS came in at -$0.43 surpassing the estimated -$0.46 by +6.52%.
Earnings released on 12 Aug 2021
EPS came in at -$3.63 falling short of the estimated -$0.40 by -807.50%.
Earnings released on 25 Jun 2021
EPS came in at -$0.90 .
Earnings released on 31 Mar 2021
EPS came in at -$0.29 .
Earnings released on 30 Sept 2020
EPS came in at -$0.30 .
GLUE Stock Performance
Access detailed GLUE performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.